Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung (VISUALIZE-2)

Vergent Bioscience

Status and phase: Enrolling; Phase 3

Conditions: Lung Cancer; Lung Metastases

Treatments: Drug: Abenacianine; Other: Near Infrared (NIR) Imaging

Study type: Interventional

Funder types: Industry

Identifiers

NCT07499674

VGT-309-3-2025

Details and patient eligibility

About

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.

Enrollment: 132 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Be willing and able to sign the informed consent and comply with study procedures.

2. Be at least 18 years of age.

3. Be scheduled for or planning to have a surgical resection of a lung lesion or mass with diagnostic and/or curative intent.

4. Meet all requirements for the planned surgery based on opinion of the surgeon, anesthesiologist, and/or other consulting physician.

5. Be able to meet the following conditions:

   1. Female participants must be of non-childbearing potential, or,
   2. If of childbearing potential, be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30 after treatment.
   3. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days after dosing.

6. Have not participated in an interventional clinical trial within the last 30 days.

Exclusion criteria

1. They have a known allergy or reaction to radiographic contrast agents, ICG, or any component of abenacianine.
2. They have received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study enrollment.
3. They have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.
4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

132 participants in 2 patient groups

Abenacianine with surgery using Standard of Care (SOC) only

Other group

Description:

Participants randomized to this arm will receive abenacianine 0.31mg/kg 12-96 hours before undergoing surgery using SOC only.

Treatment:

Drug: Abenacianine

Abenacianine with surgery using Standard of Care plus Near infrared (NIR) imaging

Other group

Description:

Participants randomized to this arm will receive abenacianine 0.31mg/kg 12-96 hours before undergoing surgery using SOC plus NIR imaging.

Treatment:

Other: Near Infrared (NIR) Imaging

Drug: Abenacianine